Literature DB >> 29467330

Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.

Marta Christov1,2, Abbe R Clark3,4, Braden Corbin1, Samy Hakroush5, Eugene P Rhee1,6, Hiroaki Saito7, Dan Brooks1, Eric Hesse7, Mary Bouxsein1,8, Niels Galjart9, Ji Yong Jung3, Peter Mundel10, Harald Jüppner1,11, Astrid Weins3,12, Anna Greka3,4.   

Abstract

Progressive chronic kidney diseases (CKDs) are on the rise worldwide. However, the sequence of events resulting in CKD progression remain poorly understood. Animal models of CKD exploring these issues are confounded by systemic toxicities or surgical interventions to acutely induce kidney injury. Here we report the generation of a CKD mouse model through the inducible podocyte-specific ablation of an essential endogenous molecule, the chromatin structure regulator CCCTC-binding factor (CTCF), which leads to rapid podocyte loss (iCTCFpod-/-). As a consequence, iCTCFpod-/- mice develop severe progressive albuminuria, hyperlipidemia, hypoalbuminemia, and impairment of renal function, and die within 8-10 weeks. CKD progression in iCTCFpod-/- mice leads to high serum phosphate and elevations in fibroblast growth factor 23 (FGF23) and parathyroid hormone that rapidly cause bone mineralization defects, increased bone resorption, and bone loss. Dissection of the timeline leading to glomerular pathology in this CKD model led to the surprising observation that podocyte ablation and the resulting glomerular filter destruction is sufficient to drive progressive CKD and osteodystrophy in the absence of interstitial fibrosis. This work introduces an animal model with significant advantages for the study of CKD progression, and it highlights the need for podocyte-protective strategies for future kidney therapeutics.

Entities:  

Keywords:  Chronic kidney disease; Endocrinology; Nephrology

Mesh:

Substances:

Year:  2018        PMID: 29467330      PMCID: PMC5916242          DOI: 10.1172/jci.insight.95091

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  52 in total

1.  Dysregulation of renal vitamin D metabolism in the uremic rat.

Authors:  Christian F Helvig; Dominic Cuerrier; Christopher M Hosfield; Breanna Ireland; Aza Z Kharebov; Jae W Kim; Navindra J Ramjit; Kara Ryder; Samir P Tabash; Andrew M Herzenberg; Tina M Epps; Martin Petkovich
Journal:  Kidney Int       Date:  2010-06-09       Impact factor: 10.612

2.  Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse.

Authors:  Kyungmin Hahm; Matvey E Lukashev; Yi Luo; William J Yang; Brian M Dolinski; Paul H Weinreb; Kenneth J Simon; Li Chun Wang; Diane R Leone; Roy R Lobb; Donald J McCrann; Normand E Allaire; Gerald S Horan; Agnes Fogo; Raghu Kalluri; Charles F Shield; Dean Sheppard; Humphrey A Gardner; Shelia M Violette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 3.  Chronic kidney disease.

Authors:  Andrew S Levey; Josef Coresh
Journal:  Lancet       Date:  2011-08-15       Impact factor: 79.321

Review 4.  Developing therapeutic 'arrows' with the precision of William Tell: the time has come for targeted therapies in kidney disease.

Authors:  Peter Mundel; Anna Greka
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-07       Impact factor: 2.894

5.  Severely reduced production of klotho in human chronic renal failure kidney.

Authors:  N Koh; T Fujimori; S Nishiguchi; A Tamori; S Shiomi; T Nakatani; K Sugimura; T Kishimoto; S Kinoshita; T Kuroki; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

Review 6.  The 3D Genome as Moderator of Chromosomal Communication.

Authors:  Job Dekker; Leonid Mirny
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

7.  Functional analysis of CTCF during mammalian limb development.

Authors:  Natalia Soshnikova; Thomas Montavon; Marion Leleu; Niels Galjart; Denis Duboule
Journal:  Dev Cell       Date:  2010-12-14       Impact factor: 12.270

8.  Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Authors:  Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

9.  Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Hejing Wang; Robert M Elashoff; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

10.  Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.

Authors:  Michael Freundlich; Michael Jofe; William G Goodman; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

View more
  6 in total

1.  Single-Cell Transcriptomics Reveal Disrupted Kidney Filter Cell-Cell Interactions after Early and Selective Podocyte Injury.

Authors:  Abbe R Clark; Jamie Marshall; Yiming Zhou; Monica S Montesinos; Haiqi Chen; Lan Nguyen; Fei Chen; Anna Greka
Journal:  Am J Pathol       Date:  2021-11-30       Impact factor: 4.307

2.  Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion.

Authors:  Valerie Clerin; Hiroshi Saito; Kevin J Filipski; An Hai Nguyen; Jeonifer Garren; Janka Kisucka; Monica Reyes; Harald Jüppner
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

Review 3.  Transcriptomics: a Solution for Renal Osteodystrophy?

Authors:  Aline Martin; Valentin David
Journal:  Curr Osteoporos Rep       Date:  2020-06       Impact factor: 5.096

4.  A clear pathway to tubulointerstitial disease: is an exclusive focus on fibrosis justified?

Authors:  Robert Safirstein
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 5.  Fibroblast growth factor 23: are we ready to use it in clinical practice?

Authors:  Annet Bouma-de Krijger; Marc G Vervloet
Journal:  J Nephrol       Date:  2020-03-04       Impact factor: 3.902

Review 6.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.